Donald E Kohan

List of Publications by Year
in descending order

135 papers	7,832 citations	61945 43 h-index	53190 85 g-index
137 all docs	137 docs citations	137 times ranked	5934 citing authors

#	Article	IF	Citations
1	Multiomic identification of factors associated with progression to cystic kidney disease in mice with nephron Ift88 disruption. American Journal of Physiology - Renal Physiology, 2022, 322, F175-F192.	1.3	3
2	Profiling renal sodium transporters in mice with nephron Ift88 disruption: Association with sex, cysts, and blood pressure. Physiological Reports, 2022, 10, e15206.	0.7	1
3	Lack of renoprotective effects of targeting the endothelin A receptor and (or) sodium glucose transporter 2 in a mouse model of Type 2 diabetic kidney disease. Canadian Journal of Physiology and Pharmacology, 2022, 100, 763-771.	0.7	4
4	Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition. Pediatric Nephrology, 2021, 36, 763-775.	0.9	17
5	New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction. Kidney International, 2021, 99, 346-349.	2.6	42
6	Individual Atrasentan Exposure is Associated With Longâ€term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. Clinical Pharmacology and Therapeutics, 2021, 109, 1631-1638.	2.3	5
7	Interâ€individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the <scp>SONAR</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 561-568.	2.2	10
8	Loss of Soluble (Pro)renin Receptor Attenuates Angiotensin-II Induced Hypertension and Renal Injury. Circulation Research, 2021, 129, 50-62.	2.0	15
9	Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2021, 30, 456-465.	1.0	19
10	Sex-Dependent Effects of Nephron Ift88 Disruption on BP, Renal Function, and Cystogenesis. Journal of the American Society of Nephrology: JASN, 2021, 32, 2210-2222.	3.0	3
11	Deletion of the Gamma Subunit of ENaC in Endothelial Cells Does Not Protect against Renal Ischemia Reperfusion Injury. International Journal of Molecular Sciences, 2021, 22, 10914.	1.8	4
12	The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1824-1832.	2.2	11
13	Renomedullary Interstitial Cell Endothelin A Receptors Regulate BP and Renal Function. Journal of the American Society of Nephrology: JASN, 2020, 31, 1555-1568.	3.0	3
14	Nephron-Specific Disruption of Polycystin-1 Induces Cyclooxygenase-2â€"Mediated Blood Pressure Reduction Independent of Cystogenesis. Journal of the American Society of Nephrology: JASN, 2020, 31, 1243-1254.	3.0	6
15	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet, The, 2019, 393, 1937-1947.	6.3	408
16	The (pro)renin receptor: an emerging player in hypertension and metabolic syndrome. Kidney International, 2019, 95, 1041-1052.	2.6	36
17	Identification of NFAT5 as a transcriptional regulator of the <i>EDN1</i> gene in collecting duct. American Journal of Physiology - Renal Physiology, 2019, 316, F481-F487.	1.3	3
18	Phenotyping a Mouse with Vascular Smooth Muscle Specific Deletion of the Gamma Subunit of the Epithelial Sodium Channel (Î³ENaC). FASEB Journal, 2019, 33, 748.7.	0.2	0

#	Article	IF	Citations
19	Baseline characteristics and enrichment results from the <scp>SONAR</scp> trial. Diabetes, Obesity and Metabolism, 2018, 20, 1829-1835.	2.2	28
20	Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes, Obesity and Metabolism, 2018, 20, 1369-1376.	2.2	60
21	Collecting duct principal, but not intercalated, cell prorenin receptor regulates renal sodium and water excretion. American Journal of Physiology - Renal Physiology, 2018, 315, F607-F617.	1.3	29
22	Nephronâ€Specific Disruption of Nitric Oxide Synthase 3 Causes Hypertension and Impaired Salt Excretion. Journal of the American Heart Association, 2018, 7, .	1.6	19
23	Response of intercalated cell BKÎ± knockâ€out mice to a high K diet. FASEB Journal, 2018, 32, 624.25.	0.2	0
24	Nephronâ€wide deletion of NOS3 impairs salt excretion and causes hypertension during high salt intake via altered NKCC2 activity. FASEB Journal, 2018, 32, 716.4.	0.2	0
25	Comparison of exposure response relationship of atrasentan between <scp>N</scp>orth <scp>A</scp>merican and <scp>A</scp>sian populations. Diabetes, Obesity and Metabolism, 2017, 19, 545-552.	2.2	4
26	Role for reactive oxygen species in flow-stimulated inner medullary collecting duct endothelin-1 production. American Journal of Physiology - Renal Physiology, 2017, 313, F514-F521.	1.3	7
27	Aldosterone does not alter endothelin B receptor signaling in the inner medullary collecting duct. Physiological Reports, 2017, 5, e13167.	0.7	2
28	The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy. Diabetes, Obesity and Metabolism, 2017, 19, 749-753.	2.2	19
29	Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial. Drugs in R and D, 2017, 17, 441-448.	1.1	6
30	Identification of adenylyl cyclase isoforms mediating parathyroid hormone- and calcitonin-stimulated cyclic AMP accumulation in distal tubule cells. BMC Nephrology, 2017, 18, 292.	0.8	2
31	Characterization of flow-regulated cortical collecting duct endothelin-1 production. Physiological Reports, 2017, 5, e13126.	0.7	5
32	Role of adenylyl cyclase 6 in the development of lithium-induced nephrogenic diabetes insipidus. JCI Insight, 2017, 2, e91042.	2.3	21
33	A Randomized Controlled Trial of the Effects of Febuxostat Therapy on Adipokines and Markers of Kidney Fibrosis in Asymptomatic Hyperuricemic Patients With Diabetic Nephropathy. Canadian Journal of Kidney Health and Disease, 2016, 3, 205435811667534.	0.6	39
34	Activation of ENaC in collecting duct cells by prorenin and its receptor PRR: involvement of Nox4-derived hydrogen peroxide. American Journal of Physiology - Renal Physiology, 2016, 310, F1243-F1250.	1.3	67
35	Collecting duct-specific knockout of nitric oxide synthase 3 impairs water excretion in a sex-dependent manner. American Journal of Physiology - Renal Physiology, 2016, 311, F1074-F1083.	1.3	13
36	Osmolar regulation of endothelin-1 production by the inner medullary collecting duct. Life Sciences, 2016, 159, 135-139.	2.0	8

#	Article	IF	Citations
37	Regulation of Mg2+ Reabsorption and Transient Receptor Potential Melastatin Type 6 Activity by cAMP Signaling. Journal of the American Society of Nephrology: JASN, 2016, 27, 804-813.	3.0	21
38	Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers. European Journal of Preventive Cardiology, 2016, 23, 758-768.	0.8	29
39	Endothelin. Pharmacological Reviews, 2016, 68, 357-418.	7.1	574
40	Role of the Collecting Duct Renin Angiotensin System in Regulation of Blood Pressure and Renal Function. Current Hypertension Reports, 2016, 18, 29.	1.5	14
41	Kidney cell-specific knockdown: anything but simple. American Journal of Physiology - Renal Physiology, 2015, 309, F1007-F1008.	1.3	1
42	Effect of mineralocorticoid treatment in mice with collecting duct-specific knockout of endothelin-1. American Journal of Physiology - Renal Physiology, 2015, 309, F1026-F1034.	1.3	10
43	Endothelin Receptor Antagonists: New Hope for Renal Protection?. Current Hypertension Reports, 2015, 17, 57.	1.5	9
44	Flow regulation of endothelin-1 production in the inner medullary collecting duct. American Journal of Physiology - Renal Physiology, 2015, 308, F541-F552.	1.3	31
45	Lack of an effect of nephron-specific deletion of adenylyl cyclase 3 on renal sodium and water excretion or arterial pressure. Physiological Reports, 2015, 3, e12316.	0.7	3
46	Activation of ENaC by AVP contributes to the urinary concentrating mechanism and dilution of plasma. American Journal of Physiology - Renal Physiology, 2015, 308, F237-F243.	1.3	29
47	Collecting Duct Principal Cell Transport Processes and Their Regulation. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 135-146.	2.2	234
48	Introduction: Basic Biology of the Renal Endothelin System. Seminars in Nephrology, 2015, 35, 121-124.	0.6	2
49	Thromboxane Prostanoid Receptors Enhance Contractions, Endothelin-1, and Oxidative Stress in Microvessels From Mice With Chronic Kidney Disease. Hypertension, 2015, 65, 1055-1063.	1.3	19
50	Nephron-specific deletion of the prorenin receptor causes a urine concentration defect. American Journal of Physiology - Renal Physiology, 2015, 309, F48-F56.	1.3	55
51	Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1568-1574.	2.2	32
52	Lack of an effect of collecting duct-specific deletion of adenylyl cyclase 3 on renal Na+ and water excretion or arterial pressure. American Journal of Physiology - Renal Physiology, 2014, 306, F597-F607.	1.3	20
53	Adenylyl Cyclase 6 Deficiency Ameliorates Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2014, 25, 232-237.	3.0	58
54	Adenylyl cyclase 4 does not regulate collecting duct water and sodium handling. Physiological Reports, 2014, 2, e00277.	0.7	8

#	ARTICLE	IF	CITATIONS
55	COX-2 mediates angiotensin II-induced (pro)renin receptor expression in the rat renal medulla. American Journal of Physiology - Renal Physiology, 2014, 307, F25-F32.	1.3	51
56	Collecting duct-specific knockout of renin attenuates angiotensin II-induced hypertension. American Journal of Physiology - Renal Physiology, 2014, 307, F931-F938.	1.3	55
57	Smooth muscle specific disruption of the endothelin-A receptor in mice reduces arterial pressure, and vascular reactivity and affects vascular development. Life Sciences, 2014, 118, 238-243.	2.0	20
58	The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2014, 25, 1083-1093.	3.0	222
59	Endothelin and endothelin antagonists in chronic kidney disease. Kidney International, 2014, 86, 896-904.	2.6	201
60	Regulation of nephron water and electrolyte transport by adenylyl cyclases. American Journal of Physiology - Renal Physiology, 2014, 306, F701-F709.	1.3	18
61	Endothelin antagonists for diabetic and nonâ€diabetic chronic kidney disease. British Journal of Clinical Pharmacology, 2013, 76, 573-579.	1.1	99
62	Role of collecting duct endothelin in control of renal function and blood pressure. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2013, 305, R659-R668.	0.9	37
63	Overexpression of Renin in the Collecting Duct Causes Elevated Blood Pressure. American Journal of Hypertension, 2013, 26, 965-972.	1.0	42
64	Adenylyl Cyclase VI Mediates Vasopressin-Stimulated ENaC Activity. Journal of the American Society of Nephrology: JASN, 2013, 24, 218-227.	3.0	35
65	Reduced ENaC activity and blood pressure in mice with genetic knockout of the insulin receptor in the renal collecting duct. American Journal of Physiology - Renal Physiology, 2013, 304, F279-F288.	1.3	35
66	Endothelin-1 inhibits sodium reabsorption by ET_Aand ET_Breceptors in the mouse cortical collecting duct. American Journal of Physiology - Renal Physiology, 2013, 305, F568-F573.	1.3	43
67	Cellular localization of adenine receptors in the rat kidney and their functional significance in the inner medullary collecting duct. American Journal of Physiology - Renal Physiology, 2013, 305, F1298-F1305.	1.3	12
68	Renal Collecting Duct NOS1 Maintains Fluidâ€“Electrolyte Homeostasis and Blood Pressure. Hypertension, 2013, 62, 91-98.	1.3	75
69	Myocardial, Smooth Muscle, Nephron, and Collecting Duct Gene Targeting Reveals the Organ Sites of Endothelin A Receptor Antagonist Fluid Retention. Journal of Pharmacology and Experimental Therapeutics, 2013, 346, 182-189.	1.3	41
70	Adenylyl cyclase VI is necessary for AVP stimulation of ENaC. FASEB Journal, 2013, 27, 911.3.	0.2	0
71	Flow stimulates inner medullary collecting duct endothelinâ€1 production. FASEB Journal, 2013, 27, 911.8.	0.2	0
72	Collecting duct-specific endothelin B receptor knockout increases ENaC activity. American Journal of Physiology - Cell Physiology, 2012, 302, C188-C194.	2.1	56

#	Article	IF	Citations
73	Na delivery and ENaC mediate flow regulation of collecting duct endothelin-1 production. American Journal of Physiology - Renal Physiology, 2012, 302, F1325-F1330.	1.3	21
74	Collecting duct-specific knockout of adenylyl cyclase type VI causes a urinary concentration defect in mice. American Journal of Physiology - Renal Physiology, 2012, 302, F78-F84.	1.3	56
75	Aldosterone-independent regulation of the epithelial Na ⁺ channel (ENaC) by vasopressin in adrenalectomized mice. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 10095-10100.	3.3	54
76	Disruption of the endothelin A receptor in the nephron causes mild fluid volume expansion. BMC Nephrology, 2012, 13, 166.	0.8	22
77	Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD). Life Sciences, 2012, 91, 739-742.	2.0	54
78	Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve?. Life Sciences, 2012, 91, 528-539.	2.0	76
79	Physiology of Endothelin and the Kidney. , 2011, 1, 883-919.		96
80	Novel Regulation of Endothelin-1 Promoter Activity by Protein Kinase C. Cell Biochemistry and Biophysics, 2011, 61, 643-650.	0.9	8
81	Addition of Atrasentan to Renin-Angiotensin System Blockade Reduces Albuminuria in Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2011, 22, 763-772.	3.0	210
82	AT1 Receptors in the Collecting Duct Directly Modulate the Concentration of Urine. Journal of the American Society of Nephrology: JASN, 2011, 22, 2237-2246.	3.0	48
83	Training the Next Generation of Nephrologists. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2564-2566.	2.2	13
84	Endothelin Antagonists in Clinical Trials: Lessons Learned. Contributions To Nephrology, 2011, 172, 255-260.	1.1	20
85	Endothelin Receptor Blockade in Patients with Diabetic Nephropathy. Contributions To Nephrology, 2011, 172, 235-242.	1.1	6
86	Regulation of Blood Pressure and Salt Homeostasis by Endothelin. Physiological Reviews, 2011, 91, 1-77.	13.1	350
87	Flow regulation of collecting duct endothelin-1 production. American Journal of Physiology - Renal Physiology, 2011, 300, F650-F656.	1.3	46
88	Flow regulation of endothelinâ€1 production in the collecting duct. FASEB Journal, 2011, 25, 1079.11.	0.2	0
89	Collecting duct endothelin system and renal water transport. FASEB Journal, 2011, 25, 1079.12.	0.2	0
90	Collecting Ductâ€Specific Knockout of Adenylyl Cyclase Type VI Causes Urinary Concentration Defect in Mice. FASEB Journal, 2011, 25, lb643.	0.2	0

#	Article	IF	Citations
91	Endothelin, hypertension and chronic kidney disease: new insights. Current Opinion in Nephrology and Hypertension, 2010, 19, 134-139.	1.0	103
92	Identification of Two Nuclear Factor of Activated T-cells (NFAT)-response Elements in the 5â€²-Upstream Regulatory Region of the ET-1 Promoter. Journal of Biological Chemistry, 2010, 285, 28520-28528.	1.6	14
93	Characterization of vasopressin-responsive collecting duct adenylyl cyclases in the mouse. American Journal of Physiology - Renal Physiology, 2010, 298, F859-F867.	1.3	36
94	Potential involvement of P2Y2 receptor in diuresis of postobstructive uropathy in rats. American Journal of Physiology - Renal Physiology, 2010, 298, F634-F642.	1.3	18
95	Bioimpedance Spectroscopy for the Estimation of Body Fluid Volumes in Mice. FASEB Journal, 2010, 24, 1025.2.	0.2	0
96	Nephrology Training Programs and Applicants. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 242-247.	2.2	14
97	Inactivation of Pkd1 in principal cells causes a more severe cystic kidney disease than in intercalated cells. Kidney International, 2009, 75, 626-633.	2.6	45
98	The Changing Phenotype of Academic Nephrologyâ€" A Future at Risk?. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 2051-2058.	2.2	3
99	Biology of endothelin receptors in the collecting duct. Kidney International, 2009, 76, 481-486.	2.6	29
100	The Chronic Kidney Disease Epidemic: A Challenge for Nephrology Training Programs. Seminars in Nephrology, 2009, 29, 539-547.	0.6	9
101	Endothelin-1 and hypertension: From bench to bedside. Current Hypertension Reports, 2008, 10, 65-69.	1.5	23
102	Role of the reninâ€"angiotensinâ€"aldosterone system in collecting duct-derived endothelin-1 regulation of blood pressureThis article is one of a selection of papers published in the special issue (part 1 of 2) on Forefronts in Endothelin.. Canadian Journal of Physiology and Pharmacology, 2008, 86, 329-336.	0.7	21
103	Novel Mechanism for Regulation of Endothelin Synthesis: Role of Extracellular pH. Cellular Physiology and Biochemistry, 2008, 21, 117-122.	1.1	4
104	Collecting Duct-Derived Endothelin Regulates Arterial Pressure and Na Excretion via Nitric Oxide. Hypertension, 2008, 51, 1605-1610.	1.3	79
105	Progress in gene targeting: using mutant mice to study renal function and disease. Kidney International, 2008, 74, 427-437.	2.6	29
106	Combined knockout of collecting duct endothelin A and B receptors causes hypertension and sodium retention. American Journal of Physiology - Renal Physiology, 2008, 295, F1635-F1640.	1.3	92
107	Role of Endothelin-1 in Clinical Hypertension. Hypertension, 2008, 52, 452-459.	1.3	150
108	Calcium regulation of endothelin-1 synthesis in rat inner medullary collecting duct. American Journal of Physiology - Renal Physiology, 2007, 293, F601-F606.	1.3	28

#	Article	IF	Citations
109	Role of prostaglandins in collecting duct-derived endothelin-1 regulation of blood pressure and water excretion. American Journal of Physiology - Renal Physiology, 2007, 293, F1805-F1810.	1.3	22
110	Altered collecting duct adenylyl cyclase content in collecting duct endothelin-1 knockout mice. BMC Nephrology, 2007, 8, 8.	0.8	15
111	Increased urinary concentrating ability of P2Y2 receptor null mice is associated with marked increase in protein abundances of AQP2 and UTâ€A in renal medulla. FASEB Journal, 2007, 21, A905.	0.2	1
112	The renal medullary endothelin system in control of sodium and water excretion and systemic blood pressure. Current Opinion in Nephrology and Hypertension, 2006, 15, 34-40.	1.0	95
113	Endothelin-1 stimulates NO production and inhibits cAMP accumulation in rat inner medullary collecting duct through independent pathways. American Journal of Physiology - Renal Physiology, 2006, 290, F1315-F1319.	1.3	59
114	Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. American Journal of Physiology - Renal Physiology, 2006, 291, F1274-F1280.	1.3	192
115	Expression and function of COX isoforms in renal medulla: evidence for regulation of salt sensitivity and blood pressure. American Journal of Physiology - Renal Physiology, 2006, 290, F542-F549.	1.3	69
116	Mechanism of Vasopressin-Induced Contraction of Renal Medullary Interstitial Cells. Nephron Physiology, 2006, 103, p119-p124.	1.5	3
117	Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. Experimental Biology and Medicine, 2006, 231, 653-95.	1.1	60
118	Adenosine triphosphate inhibits endothelin-1 production by rat inner medullary collecting duct cells. Experimental Biology and Medicine, 2006, 231, 1006-9.	1.1	8
119	Thiazolidinediones expand body fluid volume through PPARÎ³ stimulation of ENaC-mediated renal salt absorption. Nature Medicine, 2005, 11, 861-866.	15.2	573
120	Collecting duct-specific knockout of endothelin-1 alters vasopressin regulation of urine osmolality. American Journal of Physiology - Renal Physiology, 2005, 288, F912-F920.	1.3	99
121	Collecting duct-specific deletion of peroxisome proliferator-activated receptor Â blocks thiazolidinedione-induced fluid retention. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9406-9411.	3.3	315
122	Lipopolysaccharide Upregulates Renal Shiga Toxin Receptors in a Primate Model of Hemolytic Uremic Syndrome. American Journal of Nephrology, 2005, 25, 536-540.	1.4	27
123	Collecting duct-specific knockout of the endothelin A receptor alters renal vasopressin responsiveness, but not sodium excretion or blood pressure. American Journal of Physiology - Renal Physiology, 2005, 289, F692-F698.	1.3	87
124	Collecting ductâ€"specific knockout of endothelin-1 causes hypertension and sodium retention. Journal of Clinical Investigation, 2004, 114, 504-511.	3.9	215
125	Collecting ductâ€"specific knockout of endothelin-1 causes hypertension and sodium retention. Journal of Clinical Investigation, 2004, 114, 504-511.	3.9	143
126	Shigatoxin-1 binding and receptor expression in human kidneys do not change with age. Pediatric Nephrology, 2003, 18, 246-253.	0.9	49

#	Article	IF	Citations
127	Physiology and pathology of endothelin-1 in renal mesangium. American Journal of Physiology - Renal Physiology, 2003, 285, F579-F589.	1.3	110
128	Thick ascending limb-specific expression of Cre recombinase. American Journal of Physiology - Renal Physiology, 2003, 285, F33-F39.	1.3	27
129	Hypoxia regulates endothelin-1 production by the inner medullary collecting duct. Translational Research, 1998, 131, 45-48.	2.4	22
130	Cytotoxic effect of Shiga toxin-1 on human proximal tubule cells11See Editorial by Kaplan, p. 648.. Kidney International, 1998, 54, 426-437.	2.6	98
131	Expression of an AQP2 Cre recombinase transgene in kidney and male reproductive system of transgenic mice. American Journal of Physiology - Cell Physiology, 1998, 275, C216-C226.	2.1	136
132	Endothelins in the normal and diseased kidney. American Journal of Kidney Diseases, 1997, 29, 2-26.	2.1	351
133	Oxidant stress regulates basal endothelin-1 production by cultured rat pulmonary endothelial cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1997, 273, L768-L774.	1.3	19
134	Effect of reactive oxygen species on endothelin-1 production by human mesangial cells. Kidney International, 1996, 49, 181-189.	2.6	107
135	Endothelin-1 induction of cyclooxygenase-2 expression in rat mesangial cells. Kidney International, 1995, 47, 53-61.	2.6	43